BIOMAT Database Logo BIOMAT Database Logo

[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. 2004

Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
Dept. of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University.

A phase I study of gemcitabine (GEM) and UFT combination chemotherapy was performed for unresectable pancreatic cancer. The regimen included UFT orally from day 1 through day 6 and from day 8 through 13, GEM intravenously on day 7 and 14, and 1 week rest as 1 course. Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps. Nine patients were enrolled in the study. Leukopenia and neutropenia of grade 3 occurred in 2 of 6 patients at level 2, and maximum tolerated dose (MTD) was considered to be 800 mg/m2 for GEM and 250 mg/m2 for UFT. Clinical effects of the patients included: 2 PR, 4 NC, and 3 PD, for a response rate of 22% (2/9 patients). Reduced CA19-9 level of less than half of that at starting time was observed in 4 of 9 (44%) patients. The recommended dose for the phase II study is GEM 800 mg/m2 and UFT 250 mg/m2 with consideration of application to outpatients and continuing courses.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females

Related Publications

Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
November 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
[Intra-arterial chemotherapy with gemcitabine (GEM) for unresectable pancreatic cancer].
November 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
[Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
May 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
[Phase II study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non small cell lung cancer].
September 2005, Gan to kagaku ryoho. Cancer & chemotherapy,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
[Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
April 2008, Gan to kagaku ryoho. Cancer & chemotherapy,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
February 2014, Cancer chemotherapy and pharmacology,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
June 2002, British journal of cancer,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
Phase I study of paclitaxel, cisplatin and 5-fluorouracil combination chemotherapy for unresectable / recurrent gastric cancer.
January 2010, Advances in medical sciences,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.
November 2017, Cancer chemotherapy and pharmacology,
Shoji Nakamori, and Masanori Tujie, and Yuji Takahashi, and Shigeru Maruhashi, and Atsushi Miyamoto, and Hiroaki Nagano, and Keizo Dono, and Koji Umeshita, and Masato Sakon, and Morito Monden
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
February 2010, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!